Allon Therapeutics, Inc.
Allon Therapeutics, Inc. is a clinical-stage biotechnology company. The company engages in the development of drugs to treat neurodegenerative diseases and disorders. It focuses on bringing to market innovative central nervous system therapies. The company's lead drug, davunetide, is proceeding in a fully enrolled pivotal phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy, under a special protocol assessment with the Food and Drug Administration. Allon Therapeutics was founded by Illana Gozes and Richard P. Burgoon on March 24, 1994 and is headquartered in Vancouver, Canada.